US equities
|
MU
$968.18
▲+4.24%
SPCX
$144.18
▼-2.96%
TSLA
$398.46
▼-2.21%
META
$614.95
▼-0.84%
SNDK
$1,357.70
▲+4.05%
NVDA
$218.13
▲+0.09%
SKHY
$160.19
▲+10.20%
GOOGL
$323.90
▲+1.04%
MU
$968.18
▲+4.24%
SPCX
$144.18
▼-2.96%
TSLA
$398.46
▼-2.21%
META
$614.95
▼-0.84%
SNDK
$1,357.70
▲+4.05%
NVDA
$218.13
▲+0.09%
SKHY
$160.19
▲+10.20%
GOOGL
$323.90
▲+1.04%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
NewAmsterdam Pharma Company N.V. - Warrant
(NQ:
NAMSW
)
8.250
UNCHANGED
Delayed Quote
Updated: 1:31 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NewAmsterdam Pharma Company N.V. - Warrant
< Previous
1
2
3
4
Next >
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 24, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
August 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
August 18, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 06, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
July 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
July 22, 2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th –
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
June 09, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
June 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
May 27, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
May 14, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 08, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
May 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
April 30, 2025
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
April 17, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
February 26, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
February 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
January 29, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
January 10, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 13, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 11, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 10, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
December 10, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
November 20, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
November 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 06, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
